risperidone
risperidone is listed in the FDA National Drug Code directory with 92 NDC codes, marketed under brand names including risperidone, RISPERDAL M-TAB, UZEDY. Available dosage forms: tablet, film coated, injection, suspension, tablet, orally disintegrating, injection, suspension, extended release, tablet.
Drug details
- Generic Name
- risperidone
- Brand Names
- risperidone, RISPERDAL M-TAB, UZEDY, RISPERDAL, RISPERDAL CONSTA, Risperidone
- Application Number
- ANDA078040
- Sponsor
- Zydus Lifesciences Limited
- NDC Codes
- 92
- Dosage Forms
- TABLET, FILM COATED, INJECTION, SUSPENSION, TABLET, ORALLY DISINTEGRATING, INJECTION, SUSPENSION, EXTENDED RELEASE, TABLET, KIT, SOLUTION
- Routes
- ORAL, SUBCUTANEOUS, INTRAMUSCULAR
- Active Ingredients
- RISPERIDONE
Indications and Usage
1 INDICATIONS AND USAGE Risperidone is an atypical antipsychotic agent indicated for: Treatment of schizophrenia ( 1.1 ) As monotherapy or adjunctive therapy with lithium or valproate, for the treatment of acute manic or mixed episodes associated with Bipolar I Disorder ( 1.2 ) Treatment of irritability associated with autistic disorder ( 1.3 ) 1.1 Schizophrenia Risperidone oral solution is indicated for the treatment of schizophrenia. Efficacy was established in 4 short-term trials in adults, 2 short-term trials in adolescents (ages 13 to 17 years), and one long-term maintenance trial in adults [see Clinical Studies (14.1) ]. 1.2 Bipolar Mania Monotherapy Risperidone oral solution is indicated for the treatment of acute manic or mixed episodes associated with Bipolar I Disorder. Efficacy was established in 2 short-term trials in adults and one short-term trial in children and adolescents (ages 10 to 17 years) [see Clinical Studies (14.2) ]. Adjunctive Therapy Risperidone oral solution adjunctive therapy with lithium or valproate is indicated for the treatment of acute manic or mixed episodes associated with Bipolar I Disorder. Efficacy was established in one short-term trial in adults [see Clinical Studies (14.3) ]. 1.3 Irritability Associated with Autistic Disorder Risperidone oral solution is indicated for the treatment of irritability associated with autistic disorder, including symptoms of aggression towards others, deliberate self- injuriousness, temper tantrums, and quickly changing moods. Efficacy was established in 3 short-term trials in children and adolescents (ages 5 to 17 years) [see Clinical Studies (14.4) ].